Kymeta Demonstrates LEO and GEO SATCOM Interoperability During Military Battle Lab Exercise
22.7.2021 16:00:00 EEST | Business Wire | Press release
Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today seamless interoperability between the Kymeta™ u8 terminal, Kepler Communications low earth orbit (LEO) satellites, and geostationary (GEO) SATCOM terminals at an annual military battle lab exercise focused on the integration of operations, intelligence, and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005039/en/
Kymeta demonstrates LEO and GEO interoperability with the u8 at technical demonstration. (Photo: Business Wire)
The u8 is the first and only terminal available today to demonstrate the automatic handover between a GEO SATCOM terminal and Kepler LEO constellation with high throughput for communications on the move (COTM) and on the pause (COTP). Today’s warfighters require access to command and control (C2) networks providing message traffic, email, VoIP, and VTCs as well as higher throughput networks for sending and receiving large amounts of data. The demonstration proved that access to C2 networks and high throughput communications is possible with a single integrated terminal, the u8.
“While today’s mobile forces operating in remote environments may have communication access through a traditional very small aperture terminal (VSAT) or legacy COTM terminals, they do not have access to the high-throughput LEO constellations,” said Rob Weitendorf, Vice President, Business Development, Kymeta. “The u8 provides the needed capacity and seamless connectivity between LEO and GEO satellites. We could not be more thrilled with the excitement our demo received from the Special Forces community at the event.”
Three stationary ground stations with GEO and LEO capabilities located in Inuvik, Canada, Redmond, WA, and Tuscon, AZ were combined with one mobile terminal at the demonstration Virginia Beach, VA. Each station had access to six Kepler LEO satellites and two GEO satellites. The change from GEO to LEO and linear to circular polarization was automated and accomplished via software only. Kymeta and Kepler’s experimentation was focused on providing high data rate point-to-point communications where data was transmitted from ground station to ground station without connection to the cloud, followed by GEO SATCOM for day-to-day operations.
Results exceeded expectations and demonstrated a significant increase in performance with lower latency, enhanced look angles, and speeds that are approaching 10X faster than earlier products with higher throughput and total data passed. Testing results included download speeds of 240 Mbps and upload speeds of 193 Mbps achieved with over 2 GB of data transferred during a single LEO pass. This capability has utility in polar regions where access to high-throughput communications is unavailable and mechanically-steered antennas struggle in low temperatures.
The demonstration further validates Kymeta’s ability to provide a LEO upgrade path for its u8 terminals and seamlessly leverage hybrid connectivity across multiple satellite constellations and ground LTE. Kymeta is the only flat-panel antenna (FPA) with electronic beam steering and no moving parts built for mobility and designed for the needs of military, public safety, and commercial customers.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005039/en/
Contact information
Business Inquiries for Kymeta:
Brenda Kuhns
Director of Marketing
Kymeta Corporation
bhuhns@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Director of PR & Content
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
